The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is driven by primary drugs including Austedo and Zepsun, used to treat Huntington's Disease (HD), Tardive Dyskinesia (TD), Cancer, and others.
Global Newcastle Disease Vaccine Market was valued at US$ 314.0 million in 2023 and is projected to surpass a valuation of US$ 458.6 million by 2032 at a CAGR of 4.3% During the Forecast Period 2024–2032.
Southeast Asia Olmesartan Market was valued at US$ 335.2 million in 2023 and is projected to surpass a valuation of US$ 518.8 million by 2032 at a CAGR of 4.3% during the forecast period 2024–2032.
Latin America insulin market was valued at US$ 2,855.1 million in 2022 and is projected to attain a valuation of US$ 3,857.50 million by 2031 at a CAGR of 3.4% during the forecast period 2023–2031.
The Global Hyaluronidase Market exhibited a valuation of US$ 852.0 million in 2023, and it is projected to reach a market valuation of US$ 1,896.8 million by 2032, with a compound annual growth rate (CAGR) of 9.3% during the forecast period of 2024-2032.
Saudi Arabia Generic Pharmaceutical Products Market was valued at US$ 3,372.37 million in 2023 and is projected to attain a valuation of US$ 5,624.78 million by 2032 at a CAGR of 5.85% During the Forecast Period 2024 to 2032.
Global Hyoscine-N-Butyl Bromide Market was valued at US$ 56.8 million in 2023 and is projected to attain a valuation of US$ 87.9 million by 2032 at a CAGR of 4.98% During the Forecast Period 2024–2032.
The global BCG tuberculosis vaccine market was valued at US$63.58 million in 2022 and is expected to attain a market valuation of US$ 91.10 million by 2031, at a CAGR of 4.5% during the forecast period (2023-2031).
The global anthrax vaccine market is expected to grow at a steady CAGR of 6.7%, fueled by increasing bioterrorism threats and growing awareness about the disease. As of 2022, the market was valued at US$ 599 million and is expected to surpass valuation of US$ 1,006.33 million by 2031.
The Global Age-Related Macular Degeneration Market was valued at US$ 11.31 billion in 2023 and is expected to reach a market size of US$ 19.72 billion by 2032 at a CAGR of 7.2% During the Forecast Period 2024–2032.